- Home
- OXSQ vs TLSI Comparison
OXSQ vs TLSI Comparison
Compare OXSQ & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OXSQ
- TLSI
- Stock Information
- Founded
- OXSQ 2003
- TLSI 2010
- Country
- OXSQ United States
- TLSI United States
- Employees
- OXSQ N/A
- TLSI N/A
- Industry
- OXSQ Blank Checks
- TLSI Medical Specialities
- Sector
- OXSQ Finance
- TLSI Health Care
- Exchange
- OXSQ Nasdaq
- TLSI Nasdaq
- Market Cap
- OXSQ 185.5M
- TLSI 130.4M
- IPO Year
- OXSQ N/A
- TLSI N/A
- Fundamental
- Price
- OXSQ $2.94
- TLSI $4.25
- Analyst Decision
- OXSQ
- TLSI Strong Buy
- Analyst Count
- OXSQ 0
- TLSI 3
- Target Price
- OXSQ N/A
- TLSI $12.67
- AVG Volume (30 Days)
- OXSQ 474.6K
- TLSI 36.5K
- Earning Date
- OXSQ 11-05-2024
- TLSI 11-12-2024
- Dividend Yield
- OXSQ 14.29%
- TLSI N/A
- EPS Growth
- OXSQ N/A
- TLSI N/A
- EPS
- OXSQ 0.05
- TLSI N/A
- Revenue
- OXSQ $47,492,283.00
- TLSI $24,736,000.00
- Revenue This Year
- OXSQ N/A
- TLSI $62.12
- Revenue Next Year
- OXSQ N/A
- TLSI $48.04
- P/E Ratio
- OXSQ $60.27
- TLSI N/A
- Revenue Growth
- OXSQ N/A
- TLSI 67.75
- 52 Week Low
- OXSQ $2.74
- TLSI $3.32
- 52 Week High
- OXSQ $3.29
- TLSI $10.42
- Technical
- Relative Strength Index (RSI)
- OXSQ 58.35
- TLSI 41.79
- Support Level
- OXSQ $2.74
- TLSI $4.16
- Resistance Level
- OXSQ $2.99
- TLSI $4.59
- Average True Range (ATR)
- OXSQ 0.03
- TLSI 0.33
- MACD
- OXSQ 0.02
- TLSI 0.04
- Stochastic Oscillator
- OXSQ 75.00
- TLSI 22.82
About OXSQ Oxford Square Capital Corp.
Oxford Square Capital Corp is a closed-end, non-diversified management investment company with a focus is to seek an attractive risk-adjusted total return by investing in corporate debt securities and collateralized loan obligation (CLO) structured finance investments that own corporate debt securities. its capital is generally used by its corporate borrowers to finance organic growth, acquisitions, recapitalizations, and working capital. The group invests in various industries such as Structured Finance, IT Consulting, Business Services, Utilities, Software, Healthcare, Telecommunication Services, Plastics Manufacturing, and Diversified Insurance.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.